Finding. Triple-negative breast-cancer cells that live through ionizing radiation do not limp. Wall, Echeverria and colleagues watch them shrink to a residual state and then repopulate. In the trough they carry more mitochondria, faster oxidative phosphorylation, denser cristae, and a fuller metabolite set. Short OPA1, the inner-membrane fusion/cristae isoform, is up. Delete OPA1 and the rewiring is gone. Genetic or pharmacologic OPA1 hits make radiation work better. When cells regrow, much of the program fades. Metabolomics and proteomics, and outside datasets, say antioxidant capacity rises with the mitochondrial metabolism.
Why this paper matters
Chemo-resistance mitochondria are a crowded literature. Radiation survivors were less mapped. Residual disease after TNBC radiotherapy is where metastases start. If that residual cell is an OPA1-addicted OXPHOS cell, you have a window and a target.
The plasticity is a warning. Wait too long and the regrown culture looks ordinary again. The drug has to meet the residual state, not the repopulated one.
How to read the score
High eighties. Radiation, TNBC, OPA1 necessity, cristae/OXPHOS, a therapeutic claim. Confidence is high in vitro, not in the clinic.
Caveats
Dish models. OPA1 is not a clean drug target. Do not withhold standard radiation from a patient to wait for an OPA1 inhibitor.
What to do with it
If you score radioresistance metabolism, this is the OPA1 paper. If you have residual-disease TNBC tissue, stain short OPA1 and cristae. Pull the knockout-plus-IR curves.